ISRG — down 7% premarket as $450M settlement, narrowed outlook overshadow beat

Intuitive Surgical posted Q3 revenue of $3.05B (+22%, beat $2.91B) and adjusted EPS of $3.00 (beat $2.65), with 15% procedure growth — but GAAP earnings took a $450M pretax antitrust-settlement charge, and management narrowed full-year da Vinci procedure growth guidance to 14–15% (midpoint held). The call also flagged a planned 3–5% cut in instrument revenue per procedure through 2027. Shares down ~7% premarket.